DSM agrees to acquire Martek

Martek is involved in the innovation, development, production and sale of high-value products from microbial sources which promote health and wellness through nutrition.

The transaction is part of DSM‘s strategy for its Nutrition cluster ‘continued value growth’ which adds a new growth platform for healthy and natural food ingredients for infant formula, other food and beverage applications, with a special focus on Polyunsaturated Fatty Acids (PUFAs) such as microbial Omega-3 DHA (docosahexaenoic acid) and Omega-6 ARA (arachidonic acid).

Martek’s growth is expected to be accelerated by DSM’s global market reach, technology base and application skill capabilities, its insights in the food, beverage and global dietary supplements markets and its strength in industrial biotechnology and related applications.

DSM will also benefit from Martek’s recent acquisition of Amerifit, a consumer business for branded dietary supplements with very specific health benefits, which it will be able to use as an additional marketing channel for both Martek as well as DSM ingredients.

Furthermore, Martek’s algal and other microbial-based biotechnology platform and its algal technology pipeline which complements DSM’s own biotechnology portfolio, is expected to deliver new nutritional and non-nutritional (industrial) growth opportunities.